PDCD1 and neoplasm: Critically, Siglec-15 and PD-L1 demonstrate mutually exclusive expression profiles in the tumor microenvironment, suggesting that Siglec-15-targeted therapies could address a critical unmet need in patients refractory to PD-1/PD-L1 inhibition [8,9].